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Background/aim: Limited data on syphilis coinfection in human immunodeficiency virus (HIV) positive cases exist in Turkey. Our aim
is to investigate syphilis coinfection and to evaluate the compatibility of the screening Architect Syphilis Tp ELISA with the fluorescent
treponemal antibody absorption (FTA-abs) confirmation test in HIV positive cases.
Materials and methods: Totally 519 HIV positive patients were included in the study. Enzyme linked fluorescent assay (ELFA) was
used as a screening test and positive samples were confirmed by line immunassay (LIA). In order to discriminate acute HIV infection
and false ELISA positivity, HIV-1 RNA PCR was performed in ELFA positive and LIA negative samples. Architect Syphilis TP ELISA
was used for the detection of total antibodies against Treponema pallidum in HIV positive patients. Positive results were confirmed by
the FTA-abs test.
Results: Out of 519 HIV-1 positive patients, IgG and IgM positivity, and only IgG positivity was detected as 1.9% and 11.4% in all the
samples, respectively. A total of 79 (15.2%) sera were positive with Architect Syphilis Tp ELISA test and 69 (13.3%) were positive with
FTA-abs test. Statistically significant, almost perfect agreement was found between Architect Syphilis Tp ELISA and FTA-abs tests
(kappa = 0.921 and P < 0.001).
Conclusion: Implementation of syphilis and HIV screening tests together among risk groups is considered to be appropriate.
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1. Introduction
Sexually transmitted infections (STIs) remain a major public
health problem all over the world. Each year around threefourths of the estimated 340 million new cases are reported
from developing countries and STIs account for 17% of
all economic losses due to treatment costs (1). Nowadays,
AIDS and syphilis are the most commonly reported sexually
transmitted diseases (2). Although the incidence of syphilis
has declined since the 1940s with the widespread use of
penicillin, this infection reemerged due to the dramatic
increase in HIV positive patients in the 1980s. In addition,
syphilis is still one of the most important causes of death
in developing countries where HIV infection is frequently
detected (3). The incidence of HIV/STI coinfection is more
common among individuals who are newly diagnosed
with HIV (4). Coinfections between HIV and Treponema
pallidum, the causative agent of syphilis, are common due
to shared routes of sexual transmission and epidemiological
similarities (3,5). HIV may affect syphilis transmission,

clinical course, and response to treatment and can also alter
its serological diagnosis (6). On the other hand, syphilis can
mimic various clinical aspects and cause cardiovascular and
neurological problems among HIV positive patients (3).
In recent years, different control programs have
been carried out throughout the world to control STIs.
Syphilis and HIV screening have been implemented
together among risk groups in some countries (1). Given
the increased rates of syphilis in HIV infected patients,
routine periodic screening (two to four times in a year, at
least once) is highly recommended (7). Recently, syphilis
coinfection in HIV infected individuals has been reported
from several countries, mostly among African Americans
(6). In Turkey, there are limited data on syphilis coinfection
in HIV positive cases. The aim of the present study was
to determine syphilis coinfection and to evaluate the
compatibility of the Architect Syphilis Tp ELISA screening
test with the confirmatory fluorescent treponemal
antibody absorption (FTA-abs) test in HIV positive cases.
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2. Materials and Methods
During the period of May 2016 to April 2017, a total of 519
confirmed HIV-1 positive serum samples of the patients
aged ≥15 years that were sent for HIV confirmation to
the Ministry of Health National HIV-AIDS and Viral
Hepatitis Reference Laboratory in Ankara, from all
provinces in Turkey, except İzmir, İstanbul, and the Thrace
Region, were included in the study. Samples with sufficient
sera for syphilis screening and FTA-abs confirmation tests
were included in the study. All samples were checked and
repeated samples were excluded. Only the first samples of
the patients were evaluated. A two-step HIV diagnostic
algorithm was performed as recommended by the Centers
for Disease Control and Prevention (CDC) (8). The
VIDAS HIV DUO Ultra (BioMérieux, France) enzyme
linked fluorescent assay was used as a screening method
for HIV suspected patients. Positive test results with
ELFA were confirmed by testing for antibody presence
with line immunoassay (LIA; Inno-LIA HIV-1/2 Score,
Fujirebio, Belgium). ELFA positive and LIA negative or
indeterminate samples were tested by reverse transcription
polymerase chain reaction (RT-PCR; Artus HIVirus-1 RTPCR, QIAGEN, Germany) to identify acute HIV infection.
HIV RNA positive specimens were evaluated as HIV
positive. The positivity of ELFA method was interpreted as
a false positive reaction in the samples without viral load.
In HIV positive patients, syphilis serostatus screening
was determined by total antibody (IgM+IgG) Architect
Syphilis TP ELISA (Abbot Diagnostics, USA) test. Samples,
which were positive by screening test, were confirmed by
the FTA-abs IgM and FTA-abs IgG (Euroimmun, Germany)
tests (Figure 1). HIV positive patients who were positive
with Architect Tp ELISA, FTA-abs IgM and FTA-abs IgG
tests were evaluated as having acute coinfection and rapid
plasma reagin (RPR) test (Omega, UK) was performed for
all these sera. IBM SPSS version 23 statistical program was
used for statistical evaluations and descriptive information
was shown by number and percentage distributions. The
agreement between ELISA and FTA-abs tests was assessed
by the kappa test. A P-value below 0.05 was considered as
statistically significant.
3. Results
Out of 519 HIV-1 positive patients, 69 (13.3%) were positive
for syphilis. IgG positivity was detected in 85.5% (59/69)
of positive patients, and IgM positivity together with IgG
positivity was detected with a rate of 14.5% (10/69). IgG
and IgM positivity was detected in 1.9% (10/519) and only
IgG positivity was detected in 11.4% (59/519) (Table 1) of
all samples. All samples, which were IgM and IgG positive
by the confirmatory test, were positive by RPR test with
≥1/32 titer.
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Figure 1. Algorithm of the laboratory diagnosis of HIV and
syphilis coinfection.

The mean age was 40.9 ± 13.4 and syphilis positivity
was most frequently detected in the 35–44 age group with
a percentage of 30.4% (21/69). This was followed by the age
groups 25–34 and 45–54 with the rates of 27.5% (19/69)
and 17.4% (12/69), respectively (Figure 2). When all the
age groups were evaluated separately, IgG positivity was
higher than the acute infection (IgM and IgG positivity)
rates (Figure 3).
HIV positivity was detected among patients who were
resident from a total of 50 different provinces for HIV
confirmation in our study. IgG positivity was determined
in patients from 20 provinces. In addition, IgM and IgG

SÖNMEZ et al. / Turk J Med Sci
Table 1. Antibody positivity rates by FTA-abs test in HIVpositive patients (n = 519).
Number (n)

Percent (%)

Only IgG positivity

59

11.4

IgM and IgG positivity

10

1.9

Negative

450

86.7

Total

519

100.0

positivity were detected in samples sent from Düzce,
Bursa, Isparta, Antalya, Adana, Ordu, Diyarbakır, and
Mardin (Figure 4).
Out of 519 HIV-1 positive patients, 79 (15.2%) were
positive with Architect Syphilis Tp ELISA test. Of the
79 ELISA reactive samples 69 (87.3%) were positive by
FTA-abs test. When the FTA-abs test was considered as
the confirmation method, sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) of the Architect Syphilis Tp ELISA test was 100%
(69/69), 97.8% (440/450), 87.3% (69/79), and 100%
(440/440), respectively. Statistically significant, almost
perfect agreement was found between Architect Syphilis
Tp ELISA and FTA-abs tests (kappa = 0.921 and P < 0.001)
(Table 2).
4. Discussion
Treponema pallidum and HIV are both sexually transmitted
agents with similar epidemiological characteristics (5).
HIV and syphilis coinfection is complex and diagnosis
of syphilis is more difficult in HIV positive patients (9).
False positive and false negative reactions have been
frequently reported in nontreponemal RPR/VDRL tests in
HIV patients. False positive reactions may occur due to
viral infections such as HIV and HCV, malignancy, drug
addiction, autoimmune diseases, and pregnancy (10).
Moreover, false negative results can be detected in all stages
of syphilis and can result from prezonal phenomenon
in the secondary stage where the antibody levels are
the highest in most cases (11). For these reasons, it is
recommended to perform treponemal tests such as ELISA
in HIV positive patients. (12). Hence a FTA-abs positive/
ELISA positive result implies that patient has treponemal
infection. Our study was planned to determine the syphilis
coinfection in HIV positive patients and also to evaluate
the compatibility of the ELISA test, which is now being
used as a screening test for syphilis diagnosis, with the
FTA-abs test.
In our study, as suggested by the European Center
for Disease Prevention and Control (ECDC) algorithm,
positive treponemal screening test results were confirmed

Figure 2. Distribution of syphilis positivity according to age
groups in HIV positive patients (n = 69).
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Figure 3. Antibody positivity rates by FTA-abs test in each age
group of HIV positive patients (n = 519).

by a second different treponemal test (13). Nowadays,
contrary to the nontreponemal (RPR and VDRL test)
tests in routine use, ELISA tests using recombinant T.
pallidum antigens that are used successfully especially
in blood banking are highly sensitive and specific
automated tests (5). A total antibody ELISA test based
on chemiluminescent enzyme immunoassay technology
using treponemal antigens with high sensitivity (≥99%)
and specificity (≥99%) was used as a screening test in the
present study. Samples, which were positive by ELISA test,
were tested by a second treponemal test, the FTA-abs test,
which is accepted as a confirmation test for syphilis.
Evaluation of our data revealed that the ELISA test
determined 15.2% and the FTA-abs test 13.3% syphilis
antibody positivity in HIV positive cases. False positivity
with the ELISA test was 1.9%. The positivity detected by the
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Figure 4. Distribution of HIV and syphilis positive patients attending from different provinces.
Table 2. Evaluation of Architect Syphilis Tp ELISA in comparison with the FTA-abs test (n = 519).
Number

Percent

Cohen’s kappa test

(n)

(%)

Kappa coefficient

P-value

Interpretation

0.921

P < 0.001

Perfect agreement

Sensitivity

69/69

100.0

Specificity

440/450

97.8

PPV*

69/79

87.3

NPV**

440/440

100.0

* Positive predictive value.
** Negative predictive value.

FTA-abs test was considered to include syphilis infection
prior to HIV infection, syphilis infection concurrently
with HIV infection, or syphilis infection after acquiring
HIV infection. When FTA-abs IgM and FTA-abs IgG
test results were evaluated, 11.4% of 13.3% cases were
determined as past syphilis infection, and 1.9% of them
were favorably interpreted as acute syphilis infection. The
incidence of syphilis coinfection in HIV-infected patients
ranges from 0.5% to 24.4% in different studies, consistent
with the frequency of 13.3% detected in our study (14). On
the other hand, the frequency of acute syphilis infection
is reported as 2%–4% in Europe and 1%–21% in North
America (15). In our study the reported 1.9% acute
syphilis infection rate in HIV positive patients was lower
than the ones reported from Rio de Janeiro (2.7%), Recife
(8.8%), Londrina (24.4%), and Porto Alegro but somewhat
higher than the rates detected in HIV infected patients
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in Eastern Nigeria (0.3%), South Nigeria (1.5%), and
Northeast Nigeria (1.7%) (14,16). The difference in the
rates of syphilis among studies may be due to sampling,
study design, different algorithms and diagnostic tests
used, and epidemiological characteristics.
Most HIV positive cases are thought to be concentrated
in İstanbul and other big cities, mainly Ankara and İzmir,
where access to information and screening tests used can
facilitate to diagnose HIV infection. Additionally, due to the
stigmatism followed by a positive HIV test, most patients
prefer not to be tested and treated in their hometown. This
could be the reason for clustering of the cases generally
in the bigger cities. Therefore, it was determined that IgG
positivity was mostly detected in the patients attending from
Ankara and IgM positivity together with IgG positivity was
detected only from patients attending from Düzce, Antalya,
Adana, Ordu, Diyarbakır, Mardin, Bursa, and Isparta among
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our study patient group. These findings indicate that the
rate of coinfection is not limited to patients from specific
provinces. In this respect, the necessary actions for control
measures need to be planned at the national level rather than
the regional level. It should also be noted that patients who
are suspected to be HIV or syphilis positive by the clinician
may have a coinfection risk. According to our results when
age groups were investigated, it was determined that the
most common syphilis positivity was detected in the 35–44
years, followed by 25–34 and 45–54 years age groups. These
age groups constitute the sexually active part of societies (9).
Consistent with our findings, similar studies have reported
that syphilis positivity was mostly detected among people
20–40 years of age, suggesting that the highest positivity for
syphilis coinfection is generally detected in this age group
(9,17).
Syphilis IgG positivity remains lifelong, even after the
treatment. Past infection (IgG positivity only) rate in our
study was higher than the acute infection (IgM and IgG
positivity) rate in all age groups. The high percentage of past
syphilis infections in HIV positive cases compared to acute
infections suggests that either syphilis coinfection is being
treated in HIV positive patients or syphilis infection has
been acquired in the pre-HIV-infection period. Due to the
effects on the immune system and common transmission
routes, HIV predisposes to other STIs and vice versa (4).
STIs facilitate HIV transmission by breaching protective
mucosal barriers and causing immune cells to migrate to
the infection site (18). Thus, the risk of HIV transmission
increases with syphilis ulcers (3). In addition, several studies
have corroborated the negative synergistic effect of syphilis
on HIV infection; during syphilis infection viral load in
blood plasma increases and CD4 cell counts decrease
transiently (19). For this reason, testing all syphilis diagnosed
patients for HIV infection is critical (20). Likewise, patients
who have been diagnosed with HIV need to be screened
for syphilis; therefore, rapid diagnosis in syphilis is very
important (21,22).
As syphilis clinical findings and serological response
may change in HIV positive patients, delayed type atypical
responses may develop in the treponemal and nontreponemal
tests; hence, the results of the diagnostic tests may be difficult
to interpret. In HIV infection, anticardiolipin, antilecithin
antibodies, and polyclonal gammopathies are formed. It is

therefore suggested that these results are biologically false
positive and do not show syphilis infection (23). Although
there are some reports of unexpected serological responses
in HIV infected patients (7), syphilis serological diagnostic
tests are evaluated among HIV positive patients in the same
way as in the normal population, in the present study.
Nowadays, ELISA tests seem to be advantageous as they
can be automated and use multiple samples at the same time
for screening purposes (13). In our study, when the Architect
Tp screening ELISA test results were evaluated by the FTAabs test, the interrater reliability of the ELISA test was almost
perfect with a sensitivity and specificity of 100% and 97.8%
respectively. Compatible with our results, Marangoni et al.
also reported the sensitivity and specificity of the ELISA
test as 99.2% and 98.4% respectively, when compared to a
second treponemal test (24). However, considering that
false positive reactions can be obtained by ELISA tests,
syphilis should not be determined with only one treponemal
test, as suggested in the ECDC algorithm, and therefore
positive results should be confirmed with a second different
treponemal test for proper diagnosis of syphilis (13).
It is thought that the presence of HIV and syphilis
coinfection in our study will raise awareness among
clinicians. In this context, timely demand for diagnostic
tests will lead to early diagnosis of the patients and prevent
the development of complications. One limitation of this
study is that as personal data (coded data) are not always
comprehensive, risk factors other than HIV and syphilis
including sociodemographic characteristics were not
assessed in this study. In addition, as the study population
does not cover all HIV positive patients of the provinces, the
rate of syphilis-HIV coinfection could not be detected at the
provincial and national levels.
In conclusion, as syphilis coinfection is detected among
HIV positive patients, implementation of syphilis and HIV
screening tests together is considered to be appropriate
among risk groups.
It is suggested that the data within this study will provide
information for public health actions, as well as development
of the target strategies in order to monitor the frequency of
syphilis coinfection and control of the transmission. Thus,
detection and treatment of undetected cases will contribute
to reducing HIV and syphilis infections in our country.
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